Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study)
Open Access
- 15 January 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (1), e52845
- https://doi.org/10.1371/journal.pone.0052845
Abstract
Improved methods for targeting HIV testing among patients most likely to be infected are required; HIDES I aimed to define the methodology of a European wide study of HIV prevalence in individuals presenting with one of eight indicator conditions/diseases (ID); sexually transmitted infection, lymphoma, cervical or anal cancer/dysplasia, herpes zoster, hepatitis B/C, mononucleosis-like illness, unexplained leukocytopenia/thrombocytopenia and seborrheic dermatitis/exanthema, and to identify those with an HIV prevalence of >0.1%, a level determined to be cost effective. A staff questionnaire was performed. From October 2009– February 2011, individuals, not known to be HIV positive, presenting with one of the ID were offered an HIV test; additional information was collected on previous HIV testing behaviour and recent medical history. A total of 3588 individuals from 16 centres were included. Sixty-six tested positive for HIV, giving an HIV prevalence of 1.8% [95% CI: 1.42–2.34]; all eight ID exceeded 0.1% prevalence. Of those testing HIV positive, 83% were male, 58% identified as MSM and 9% were injecting drug users. Twenty percent reported previously having potentially HIV-related symptoms and 52% had previously tested HIV negative (median time since last test: 1.58 years); which together with the median CD4 count at diagnosis (400 cell/uL) adds weight to this strategy being effective in diagnosing HIV at an earlier stage. A positive test was more likely for non-white individuals, MSM, injecting drug users and those testing in non-Northern regions. HIDES I describes an effective strategy to detect undiagnosed HIV infection. All eight ID fulfilled the >0.1% criterion for cost effectiveness. All individuals presenting to any health care setting with one of these ID should be strongly recommended an HIV test. A strategy is being developed in collaboration with ECDC and WHO Europe to guide the implementation of this novel public health initiative across Europe.Keywords
This publication has 21 references indexed in Scilit:
- HIV Testing in Non-Traditional Settings – The HINTS Study: A Multi-Centre Observational Study of Feasibility and AcceptabilityPLOS ONE, 2012
- Projected life expectancy of people with HIV according to timing of diagnosisAIDS, 2012
- The Economic Burden of Late Entry Into Medical Care for Patients With HIV InfectionMedical Care, 2010
- Routine HIV Screening in France: Clinical Impact and Cost-EffectivenessPLOS ONE, 2010
- Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic FailureJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high‐risk men who have sex with menHIV Medicine, 2009
- Indicator disease‐guided testing for HIV – the next step for Europe?HIV Medicine, 2008
- Diagnosed and undiagnosed HIV‐infected populations in EuropeHIV Medicine, 2008
- Infections Prevented by Increasing HIV Serostatus Awareness in the United States, 2001 to 2004JAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Late diagnosis of HIV infection: major consequences and missed opportunitiesCurrent Opinion in Infectious Diseases, 2008